Brief: Kiora Pharmaceuticals On Jan 25, Got Into Exclusive License Deal With Théa Open Innovation Sas

Kiora Pharmaceuticals

31/01/2024 23:39

Jan 31 (Reuters) - Kiora Pharmaceuticals Inc  KPRX.O :
    * KIORA PHARMACEUTICALS: ON JAN 25, GOT INTO EXCLUSIVE
LICENSE
DEAL WITH THÉA OPEN INNOVATION SAS FOR CO'S KIO-301 MOLECULAR
PHOTOSWITCH PRODUCT
    * KIORA PHARMACEUTICALS: TO BE RESPONSIBLE FOR DESIGN,
IMPLEMENTATION OF CLINICAL DEVELOPMENT OF KIO-301 THROUGH PHASE
2
    * KIORA PHARMACEUTICALS INC: TOI WILL BE RESPONSIBLE AT ITS
OWN
COST FOR PHASE 3 CLINICAL TRIALS AND FOR SECURING REGIONAL
MARKETING AUTHORIZATIONS
    * KIORA PHARMACEUTICALS INC: TOI WILL PAY CO UP-FRONT
PAYMENT OF
$16.0 MILLION
    * KIORA PHARMACEUTICALS: ELIGIBLE TO GET MILESTONE PAYMENTS
OF UP
TO ABOUT $285 MILLION ON ACHIEVEMENT OF SOME MILESTONES
    * KIORA PHARMACEUTICALS: GRANTED TOI EXCLUSIVE WORLDWIDE
DEVELOPMENT AND COMMERCIALIZATION RIGHTS, EXCLUDING ASIA, TO
KIO-301

Source text for Eikon:  ID:n0001372514-24-000007 
Further company coverage:  KPRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))